We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 2.98 | 1.85% | 163.79 | 164.25 | 160.74 | 161.85 | 5,850,104 | 01:00:00 |
From May 2019 to May 2024
By Josh Beckerman
Voyager Therapeutics Inc. shares fell 15% to $9.62 after hours as the gene therapy company reported the terminations of its tau and alpha-synuclein vectorized antibody collaborations with AbbVie Inc.
Voyager retains full rights to the vectorization technology and certain novel vectorized antibodies developed as part of the collaborations.
"Through the tau and alpha-synuclein collaborations, we believe we have made considerable progress against targets for neurodegenerative diseases," the company said.
Voyager doesn't anticipate any changes to its cash runway guidance.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
August 03, 2020 19:06 ET (23:06 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
